Tirsa E. Van Westering
South Parks Road
Oxford, ENG, United Kingdom
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Timing matters: Exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy.
Journal: Molecular therapy. Nucleic acids
Published: January 12, 2026
Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy.
Journal: Molecular & cellular proteomics : MCP
Published: September 09, 2020
Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology.
Journal: Journal of cachexia, sarcopenia and muscle
Published: August 21, 2019
Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
Journal: Human molecular genetics
Published: July 26, 2018
Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice.
Journal: EBioMedicine
Published: March 03, 2018
Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy.
Journal: Molecules (Basel, Switzerland)
Published: March 31, 2015
Seasonal induction of GABAergic excitation in the central mammalian clock.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 01, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026